Richard Peck

Founder at Cellestia Biotech AG

73 year

Health Services

Health Technology

Profile

Richard Peck is the founder of Cellestia Biotech AG, which was founded in 2014.
He held the title of Head-Regulatory Affairs at the company.
Dr. Peck's former job was as Head-Regulatory Affairs at Finox Biotech AG.

Richard Peck active positions

Companies	Position	Start
Cellestia Biotech AG Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.	Founder	01/01/2014

All active positions of Richard Peck

Former positions of Richard Peck

Companies	Position	End
Finox Biotech AG Finox Biotech AG Medical/Nursing ServicesHealth Services Finox AG specializes in developing fertility drugs. Its products include BEMFOLA, a recombinant-human follicle-stimulating hormone. The company was founded by Michel Wilhelm in 2007 and is headquartered in Burgdorf, Switzerland.	General Counsel	-

See the detail of Richard Peck's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Richard Peck's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Finox Biotech AG Finox Biotech AG Medical/Nursing ServicesHealth Services Finox AG specializes in developing fertility drugs. Its products include BEMFOLA, a recombinant-human follicle-stimulating hormone. The company was founded by Michel Wilhelm in 2007 and is headquartered in Burgdorf, Switzerland.	Health Services
Cellestia Biotech AG Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.	Health Technology